Compare Hewlett Packard Enterprise Co (HPE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Recursion Pharmaceuticals Inc — how do they compare? Hewlett Packard Enterprise Co trades at $71.89 (market cap $94.25B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Hewlett Packard Enterprise Co is far larger — about 44× Recursion Pharmaceuticals Inc's market cap, and Hewlett Packard Enterprise Co pays a 0.8% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| HPE | RXRX | |
|---|---|---|
Market Cap | $94.25B | $2.14B |
Volume | 16,060,854 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $72.12 | $6.79 |
52-Week Low | $20.01 | $2.84 |
Typical Hold Time | 33 Days | 22 Days |
Enterprise Value | $108.28B | $1.66B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE stock trades at $72.115, up 2.2% today and near its all-time high, driven by strong AI infrastructure demand and a recent $1.2 billion server order from Vultr. The technical outlook is bullish, with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, revenue growth accelerated to $34.3 billion in 2025, but net income margin compressed to 0.16% due to higher costs, while 2026 projections show a rebound to $41.9 billion revenue and $2.8 billion net income.
The outlook remains positive given AI-driven guidance raises and analyst upgrades, but risks include execution on Juniper integration, debt levels rising to 29.48% of assets, and valuation multiples above sector averages. The stock offers growth exposure to AI infrastructure, yet investors face volatility near record highs.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
